Short answer
Adicet Bio Inc (ACET) filed its Q3 2018 10-Q quarterly report on Nov 13, 2018 for the quarter ended Sep 30, 2018.
Adicet Bio Inc Q3 2018 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales or collaboration revenue
- Net loss $8.4M vs $3.3M YoY, operating loss $9.0M vs $3.9M
- Research and development $6.8M vs $3.3M, general and administrative $2.3M vs $0.6M
- Cash, equivalents and marketable securities $115.4M at September 30, 2018, IPO proceeds $89.4M
- Operating cash outflow $27.8M for nine months, management expects funding through 2020 but anticipates additional financing needs
Risk Factors
- No material changes to 2017 Form 10-K risk factors
- Existing risks updated through June 30, 2018 Form 10-Q
- Forward-looking statements subject to management assumptions and limited control
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Adicet Bio Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.